Pub. Date : 2007 Jan
PMID : 17237266
6 Functional Relationships(s)Download |
Sentence | Compound Name | Protein Name | Organism |
| 1 | In renal cell carcinoma (RCC) models, maximal cytotoxicity of the proteasome inhibitor bortezomib is dependent on efficient blockade of constitutive nuclear factor kappaB (NF-kappaB) activity. | Bortezomib | nuclear factor kappa B subunit 1 | Homo sapiens |
| 2 | Evaluation of the effects of drug sequencing on inhibition of NF-kappaB activity revealed that EGFR-TKI pretreatment markedly augmented the NF-kappaB inhibitory effect of bortezomib, whereas bortezomib preexposure resulted in suboptimal NF-kappaB blockade and thus provides a biochemical explanation for the drug interaction results. | Bortezomib | nuclear factor kappa B subunit 1 | Homo sapiens |
| 3 | Evaluation of the effects of drug sequencing on inhibition of NF-kappaB activity revealed that EGFR-TKI pretreatment markedly augmented the NF-kappaB inhibitory effect of bortezomib, whereas bortezomib preexposure resulted in suboptimal NF-kappaB blockade and thus provides a biochemical explanation for the drug interaction results. | Bortezomib | nuclear factor kappa B subunit 1 | Homo sapiens |
| 4 | Evaluation of the effects of drug sequencing on inhibition of NF-kappaB activity revealed that EGFR-TKI pretreatment markedly augmented the NF-kappaB inhibitory effect of bortezomib, whereas bortezomib preexposure resulted in suboptimal NF-kappaB blockade and thus provides a biochemical explanation for the drug interaction results. | Bortezomib | nuclear factor kappa B subunit 1 | Homo sapiens |
| 5 | Evaluation of the effects of drug sequencing on inhibition of NF-kappaB activity revealed that EGFR-TKI pretreatment markedly augmented the NF-kappaB inhibitory effect of bortezomib, whereas bortezomib preexposure resulted in suboptimal NF-kappaB blockade and thus provides a biochemical explanation for the drug interaction results. | Bortezomib | nuclear factor kappa B subunit 1 | Homo sapiens |
| 6 | Pretreatment with an EGFR-TKI sensitizes to bortezomib-mediated cytotoxicity by inhibiting constitutive NF-kappaB activity. | Bortezomib | nuclear factor kappa B subunit 1 | Homo sapiens |